论文信息 - SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.

SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.

7514 Background: EGFR mutant NSCLC is exquisitely sensitive to EGFR tyrosine kinase inhibitors (TKIs). Retrospective data suggests adjuvant TKIs may improve outcomes. This trial is the first to pro...